Analysis set: safety||D- VTd||11||Table 3:	Summary of Subject Disposition; Safety Analysis Set (Study 54767414MMY1001)----11 subjects in the VTd treatment regimen(Table 3).
Subjects who discontinued treatment||DVd||2 (33.3%)||Table 3:	Summary of Subject Disposition; Safety Analysis Set (Study 54767414MMY1001)----The 2 (33%) subjects in the Vd treatment regimen discontinued study treatment for elective ASCT.
Subjects who discontinued treatment|Reason for discontinuation|Adverse event||D- Pom-dex||1 (4.2%)||Table 3:	Summary of Subject Disposition; Safety Analysis Set (Study 54767414MMY1001)|||Subjects who discontinued treatment|Reason for discontinuation|Physician decision||D- Pom-dex||1 (4.2%)||Table 3:	Summary of Subject Disposition; Safety Analysis Set (Study 54767414MMY1001)----In the Pom-dex treatment regimen, 1 (4%) subject each discontinued due to AE and physician’s decision.
Subjects who discontinued treatment|Reason for discontinuation|Adverse event||Total||1 (2.0%)||Table 3:	Summary of Subject Disposition; Safety Analysis Set (Study 54767414MMY1001)|||Subjects who discontinued treatment|Reason for discontinuation|Physician decision||Total||1 (2.0%)||Table 3:	Summary of Subject Disposition; Safety Analysis Set (Study 54767414MMY1001)|||Subjects who discontinued treatment|Reason for discontinuation|Progressive disease||Total||3 (6.1%)||Table 3:	Summary of Subject Disposition; Safety Analysis Set (Study 54767414MMY1001)|||Subjects who discontinued treatment|Reason for discontinuation|Other||Total||8 (16.3%)||Table 3:	Summary of Subject Disposition; Safety Analysis Set (Study 54767414MMY1001)----Thirteen (27%) subjects discontinued study treatment; 8 (16%) subjects due to “other” reasons (all 8 were discontinued electively for autologous stem cell transplant [ASCT]), 3 (6%) subjects due to progressive disease and 1 (2%) subject each due to an AE and physician’s decision.
System organ class/preferred term|Infections And Infestations|Pneumonia||Total||3 (6.1%)||Table 9:	Number of Subjects With 1 or More Treatment-emergent Serious Adverse Events by MedDRA System-organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY1001)----The most commonly reported SAE was pneumonia (3 subjects; 6%).
Total number of subjects with infusion related reactions||Total||24 (49.0%)||Table 10:	Number of Subjects With 1 or More Treatment-emergent Infusion Related Reactions by MedDRA System-organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY1001)----Infusion related reactions were reported in 24 (49%) subjects during the study.
